TSO3 Receives FDA 510(k) Clearance for Universal Design of STERIZONE® VP4 Sterilizer

Inogen Announces Fourth Quarter and Full Year 2015 Financial Results and Updates 2016 Guidance

Second Sight to Announce Five-Year Data from Argus II Clinical Trial Program

Study Results Will Be Presented at 39^th Annual Macula Society Meeting

SYLMAR, Calif. -- Second Sight Medical Products, Inc. (EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, announced it will unveil five-year outcomes associated with the Argus^® II Retinal Prosthesis System ("Argus II") during the 39th Annual Macula Society Meeting, being held February 24-27, 2016, at Eden Roc Miami Beach. James Handa, MD, the Robert Bond Welch Professor of Ophthalmology at the Johns Hopkins University Wilmer Eye Institute, will present the data for the first time during a session on Inherited Retinal Degeneration on Wednesday, February 24th at 6:12 p.m. Eastern Time.

Electromed, Inc. Reports Record $6 Million Dollar Quarter

Operating Income Increased 180%

NEW PRAGUE, Minn.-- Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for the three- and six-month periods ended December 31, 2015.

Net revenues for the second quarter of fiscal 2016 were $6.26 million, a 28.3% or $1.38 million increase, compared to the second quarter of fiscal 2015. Growth in total net revenues was attributable to strong results in the home care market in which revenue increased by 21.5%, or $0.97 million, compared to the same period of fiscal 2015. Home care sales, which accounted for nearly 88% of revenues, increased due to a higher number of approvals, a higher conversion rate of referrals to approvals, and a higher average selling price from third party payers, such as insurance companies, Medicare and Medicaid, for the Company’s SmartVest^® products.